Abraxis Bioscience competitive analysis

Latest publications and patents of Abraxis Bioscience New

Explore the latest publications and patents granted to Abraxis Bioscience, showcasing their recent innovations and technological advancements.

Last updated on: Sep 24, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Abraxis Bioscience

Sep 29, 2021Methods Of Treating Pancreatic CancerRevoked
Jun 24, 2020Combinations And Modes Of Administration Of Therapeutic Agents And Combination TherapyRevoked
Apr 22, 2020Methods Of Treating Lung CancerRevoked
Jan 17, 2018Drugs With Improved Hydrophobicity For Incorporation In Medical DevicesNo Opposition Filed Within Time Limit
Jul 26, 2017Methods Of Treating Bladder CancerRevoked

Explore Abraxis Bioscience's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 25, 2025
Patent NumberGrant DateTitleTotal Oppositions
Sep 29, 2021Methods Of Treating Pancreatic Cancer3
Jun 24, 2020Combinations And Modes Of Administration Of Therapeutic Agents And Combination Therapy2
Apr 22, 2020Methods Of Treating Lung Cancer1
Jul 26, 2017Methods Of Treating Bladder Cancer1

Latest PTAB cases involving Abraxis Bioscience

Discover the latest PTAB cases involving Abraxis Bioscience, highlighting their recent legal challenges and patent disputes.

Last updated on: Sep 30, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Abraxis Bioscience

IPR2018-00163Nov 9, 2017CIPLAABRAXIS BIOSCIENCESInstitution Denied
IPR2018-00162Nov 9, 2017CIPLAABRAXIS BIOSCIENCESInstitution Denied
IPR2018-00153Nov 9, 2017APOTEXABRAXIS BIOSCIENCESTerminated-Settled
IPR2018-00152Nov 9, 2017APOTEXABRAXIS BIOSCIENCETerminated-Settled
IPR2018-00151Nov 9, 2017APOTEXABRAXIS BIOSCIENCETerminated
IPR2017-01104Apr 4, 2017ACTAVISABRAXIS BIOSCIENCETerminated-Settled
IPR2017-01103Apr 4, 2017ACTAVISABRAXIS BIOSCIENCETerminated-Settled
IPR2017-01101Apr 4, 2017ACTAVISABRAXIS BIOSCIENCETerminated-Settled
IPR2017-01100Apr 4, 2017ACTAVISABRAXIS BIOSCIENCEInstitution Denied

Peer Comparison New

IP litigation analysis comparing Abraxis Bioscience with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Sep 25, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases FacedStrategy Type
ABRAXIS BIOSCIENCE - 7 - 6Non-Active
ACTAVIS - - 5 - Highly Aggressive
GENERICS UK211 - - - Highly Aggressive
TEVA PHARMACEUTICALS20515 - 12Highly Aggressive